MétaCan
Menu
← Back to cohort
Record W2921227782 · doi:10.1093/jcag/gwz006.124

A125 PERIOPERATIVE ANTI-TNFα AGENTS AND POST-OPERATIVE INFECTIOUS COMPLICATIONS IN ELECTIVE SURGICAL IBD PATIENTS

2019· article· en· W2921227782 on OpenAlexaff
Alexandra C. Istl, Mu Yang, Claire E. Parker, Katherine Fleshner, Leonardo Guizzetti, Vipul Jairath

Bibliographic record

VenueJournal of the Canadian Association of Gastroenterology · 2019
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsRobarts Clinical TrialsWestern University
Fundersnot available
KeywordsMedicineInfliximabPerioperativeUlcerative colitisMeta-analysisAdalimumabElective surgeryInflammatory bowel diseaseCrohn's diseaseSurgeryComplicationRelative riskInternal medicineMEDLINEDiseaseConfidence interval

Abstract

fetched live from OpenAlex

Biologic agents are commonly interrupted prior to surgical intervention for inflammatory bowel disease (IBD) to avoid risk of infection. Previous reviews report increased rates of post-operative infections, however, these included patients undergoing emergent surgeries, which have an inherently higher complication risk. To conduct a systematic review and meta-analysis aims to quantify the risk of post-operative infection in IBD patients on biologic therapy undergoing elective surgery. EMBASE, Medline, Cochrane CENTRAL, clinialtrials.gov, and the International Clinical Trials Registry Platform were searched without language restriction. Studies comparing infection rates for IBD patients on and off biologic therapy undergoing elective (non-emergent) surgery were eligible. The primary outcome was any post-operative infection. Secondary outcomes included overall complications and rates of specific infections. Meta-analyses were performed using a random-effects models. Studies were weighted by the inverse variance method. Pooled risk ratios were calculated for infectious complications, overall complications, and specific infectious outcomes. Fourteen studies totaling 3544 patients were included. Six assessed Crohn’s disease (CD), five assessed ulcerative colitis (UC), and three assessed both. All studies examined outcomes after elective surgeries for IBD. Infliximab was the intervention in eight studies, adalimumab in one, and five assessed any anti-TNFa. Pooled estimates of infectious complication rates were 13.7% [95% CI 8.9, 20.6] and 16.7% [95% CI 9.4, 27.8] in the control and therapy groups respectively, [risk difference 0.08% [95% CI -10.8, 11.0, p=0.99]]. For total complications, the between group risk difference was 3.5% [95% CI -1.3, 8.3, p=0.15]. No significant difference was identified between control and therapy groups for anastomotic leak, surgical site infection, urinary tract infection, nosocomial pneumonia, or C. difficile infection. In the setting of elective surgery, no difference in the risk of post-operative infections or other complications was observed in IBD on biologic therapy at the time of surgery versus those who were not. Pooled analysis of studies reporting overall infectious complications. Absolute risk difference between groups is 0.08% [95% CI -10.8, 11.0, p=0.99]. RD - risk difference. Heterogeneity was moderate to high. None

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.006
metaresearch head score (Gemma)0.019
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.006
Threshold uncertainty score0.030

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0060.019
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0060.020
Bibliometrics0.0040.005
Science and technology studies0.0000.000
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.003
GPT teacher head0.217
Teacher spread0.214 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the Canadian Association of Gastroenterology→Same topicInflammatory Bowel Disease→French-language works237,207→